Evidence of this approach has been provided in pre-clinical settings by the infusion of anti-RANKL antibody, which depleted AIRE-expressing TEC in the thymus and allowed self/melanoma-reactive T cells to escape negative selection and increase in the peripheral pool. This evidence concerns the gene TNFSF11 and melanoma.